Nanoplasmonic quantification of tumour-derived extracellular vesicles in plasma microsamples for diagnosis and treatment monitoring

Kai Liang, Fei Liu, Jia Fan, Dali Sun, Chang Liu, Christopher J. Lyon, David W. Bernard, Yan Li, Kenji Yokoi, Matthew H. Katz, Eugene J. Koay, Zhen Zhao, Ye Hu

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Tumour-derived extracellular vesicles (EVs) are of increasing interest as a resource of diagnostic biomarkers. However, most EV assays require large samples and are time-consuming, low-throughput and costly, and thus impractical for clinical use. Here, we describe a rapid, ultrasensitive and inexpensive nanoplasmon-enhanced scattering (nPES) assay that directly quantifies tumour-derived EVs from as little as 1 μl of plasma. The assay uses the binding of antibody-conjugated gold nanospheres and nanorods to EVs captured by EV-specific antibodies on a sensor chip to produce a local plasmon effect that enhances tumour-derived EV detection sensitivity and specificity. We identified a pancreatic cancer EV biomarker, ephrin type-A receptor 2 (EphA2), and demonstrate that an nPES assay for EphA2-EVs distinguishes pancreatic cancer patients from pancreatitis patients and healthy subjects. EphA2-EVs were also informative in staging tumour progression and in detecting early responses to neoadjuvant therapy, with better performance than a conventional enzyme-linked immunosorbent assay. The nPES assay can be easily refined for clinical use, and readily adapted for diagnosis and monitoring of other conditions with disease-specific EV biomarkers.

Original languageEnglish (US)
Article number0021
JournalNature Biomedical Engineering
Volume1
Issue number4
DOIs
StatePublished - Apr 10 2017

Fingerprint

Tumors
Assays
Plasmas
Monitoring
Biomarkers
Neoplasms
Scattering
Antibodies
Therapeutics
Eph Family Receptors
Immunosorbents
Pancreatic Neoplasms
Nanospheres
Nanorods
Gold
Extracellular Vesicles
Enzymes
Nanotubes
Throughput
Neoadjuvant Therapy

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Computer Science Applications

Cite this

Nanoplasmonic quantification of tumour-derived extracellular vesicles in plasma microsamples for diagnosis and treatment monitoring. / Liang, Kai; Liu, Fei; Fan, Jia; Sun, Dali; Liu, Chang; Lyon, Christopher J.; Bernard, David W.; Li, Yan; Yokoi, Kenji; Katz, Matthew H.; Koay, Eugene J.; Zhao, Zhen; Hu, Ye.

In: Nature Biomedical Engineering, Vol. 1, No. 4, 0021, 10.04.2017.

Research output: Contribution to journalArticle

Liang, Kai ; Liu, Fei ; Fan, Jia ; Sun, Dali ; Liu, Chang ; Lyon, Christopher J. ; Bernard, David W. ; Li, Yan ; Yokoi, Kenji ; Katz, Matthew H. ; Koay, Eugene J. ; Zhao, Zhen ; Hu, Ye. / Nanoplasmonic quantification of tumour-derived extracellular vesicles in plasma microsamples for diagnosis and treatment monitoring. In: Nature Biomedical Engineering. 2017 ; Vol. 1, No. 4.
@article{3c34d82134b243bc9b714e7df9e52097,
title = "Nanoplasmonic quantification of tumour-derived extracellular vesicles in plasma microsamples for diagnosis and treatment monitoring",
abstract = "Tumour-derived extracellular vesicles (EVs) are of increasing interest as a resource of diagnostic biomarkers. However, most EV assays require large samples and are time-consuming, low-throughput and costly, and thus impractical for clinical use. Here, we describe a rapid, ultrasensitive and inexpensive nanoplasmon-enhanced scattering (nPES) assay that directly quantifies tumour-derived EVs from as little as 1 μl of plasma. The assay uses the binding of antibody-conjugated gold nanospheres and nanorods to EVs captured by EV-specific antibodies on a sensor chip to produce a local plasmon effect that enhances tumour-derived EV detection sensitivity and specificity. We identified a pancreatic cancer EV biomarker, ephrin type-A receptor 2 (EphA2), and demonstrate that an nPES assay for EphA2-EVs distinguishes pancreatic cancer patients from pancreatitis patients and healthy subjects. EphA2-EVs were also informative in staging tumour progression and in detecting early responses to neoadjuvant therapy, with better performance than a conventional enzyme-linked immunosorbent assay. The nPES assay can be easily refined for clinical use, and readily adapted for diagnosis and monitoring of other conditions with disease-specific EV biomarkers.",
author = "Kai Liang and Fei Liu and Jia Fan and Dali Sun and Chang Liu and Lyon, {Christopher J.} and Bernard, {David W.} and Yan Li and Kenji Yokoi and Katz, {Matthew H.} and Koay, {Eugene J.} and Zhen Zhao and Ye Hu",
year = "2017",
month = "4",
day = "10",
doi = "10.1038/s41551-016-0021",
language = "English (US)",
volume = "1",
journal = "Nature Biomedical Engineering",
issn = "2157-846X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Nanoplasmonic quantification of tumour-derived extracellular vesicles in plasma microsamples for diagnosis and treatment monitoring

AU - Liang, Kai

AU - Liu, Fei

AU - Fan, Jia

AU - Sun, Dali

AU - Liu, Chang

AU - Lyon, Christopher J.

AU - Bernard, David W.

AU - Li, Yan

AU - Yokoi, Kenji

AU - Katz, Matthew H.

AU - Koay, Eugene J.

AU - Zhao, Zhen

AU - Hu, Ye

PY - 2017/4/10

Y1 - 2017/4/10

N2 - Tumour-derived extracellular vesicles (EVs) are of increasing interest as a resource of diagnostic biomarkers. However, most EV assays require large samples and are time-consuming, low-throughput and costly, and thus impractical for clinical use. Here, we describe a rapid, ultrasensitive and inexpensive nanoplasmon-enhanced scattering (nPES) assay that directly quantifies tumour-derived EVs from as little as 1 μl of plasma. The assay uses the binding of antibody-conjugated gold nanospheres and nanorods to EVs captured by EV-specific antibodies on a sensor chip to produce a local plasmon effect that enhances tumour-derived EV detection sensitivity and specificity. We identified a pancreatic cancer EV biomarker, ephrin type-A receptor 2 (EphA2), and demonstrate that an nPES assay for EphA2-EVs distinguishes pancreatic cancer patients from pancreatitis patients and healthy subjects. EphA2-EVs were also informative in staging tumour progression and in detecting early responses to neoadjuvant therapy, with better performance than a conventional enzyme-linked immunosorbent assay. The nPES assay can be easily refined for clinical use, and readily adapted for diagnosis and monitoring of other conditions with disease-specific EV biomarkers.

AB - Tumour-derived extracellular vesicles (EVs) are of increasing interest as a resource of diagnostic biomarkers. However, most EV assays require large samples and are time-consuming, low-throughput and costly, and thus impractical for clinical use. Here, we describe a rapid, ultrasensitive and inexpensive nanoplasmon-enhanced scattering (nPES) assay that directly quantifies tumour-derived EVs from as little as 1 μl of plasma. The assay uses the binding of antibody-conjugated gold nanospheres and nanorods to EVs captured by EV-specific antibodies on a sensor chip to produce a local plasmon effect that enhances tumour-derived EV detection sensitivity and specificity. We identified a pancreatic cancer EV biomarker, ephrin type-A receptor 2 (EphA2), and demonstrate that an nPES assay for EphA2-EVs distinguishes pancreatic cancer patients from pancreatitis patients and healthy subjects. EphA2-EVs were also informative in staging tumour progression and in detecting early responses to neoadjuvant therapy, with better performance than a conventional enzyme-linked immunosorbent assay. The nPES assay can be easily refined for clinical use, and readily adapted for diagnosis and monitoring of other conditions with disease-specific EV biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=85021400993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021400993&partnerID=8YFLogxK

U2 - 10.1038/s41551-016-0021

DO - 10.1038/s41551-016-0021

M3 - Article

VL - 1

JO - Nature Biomedical Engineering

JF - Nature Biomedical Engineering

SN - 2157-846X

IS - 4

M1 - 0021

ER -